Stereotactic radiosurgery (SRS) has become an important treatment option for intracranial lesions and has recently been adapted to treat lesions outside the brain. Many studies have shown the effectiveness of SRS for the treatment of benign and metastatic tumors. Although DNA damage has been thought to be the principal form of radiation-induced damage, recent studies have shown that vascular endothelial damage is perhaps more important in the setting of high radiation doses per fraction such as those used in SRS. Furthermore, it has been shown that molecular responses to radiation differ based on dose per fraction. The principles of classical radiobiology are reviewed with explanation on why fractionation of radiotherapy allows optimization of the therapeutic ratio. The current understanding of the molecular responses that occur soon after the delivery of high radiation doses per fraction is also reviewed. A summary of current clinical evidence of radiation tolerance to SRS of brain, brainstem, optic chiasm and spinal cord is also provided. Recent advances in understanding the molecular basis of SRS response have uncovered a different biological response than previously thought.
Introduction
Over the last few decades, intracranial stereotactic radiosurgery (SRS) has become an important treatment option for patients with benign and metastatic lesions of the brain. SRS is a highly specialized technique that delivers a single or few (5 or less) dose(s) of highly conformal radiation to the target(s) with submillimeter precision (1). Because of the high dose per fraction of radiation used, it is very important to accurately localize and immobilize the target as well as achieve a sharp dose gradient ("dose falloff") outside the tumor volume in order to maximally spare the surrounding normal tissue. When initially introduced, large doses per fraction in SRS defied conventional wisdom in radiation biology and the fear of "late radiation effects" was prevalent. However, both prospective trials and retrospective studies have shown that SRS can achieve excellent local control with acceptable toxicity for both metastatic disease (2) as well as for benign conditions such as meningiomas (3) and functional disorders such as medically and surgically refractory trigeminal neuralgia (4).
Similar to SRS, stereotactic body radiotherapy (SBRT) is a radiation delivery technique in which highly conformal large doses in a single or few fractions are delivered to an extracranial target within the body (5). The translation of SRS to SBRT was hindered by two main factors: organ movement and accurate localization of the target (6) . Tumors in the body are susceptible to motion secondary to normal physiological functions such as breathing and digestion. For SBRT to be effective (i.e. maximal tumor control with minimal side effects), the planning target must be mostly tumor and hence large planned margin around the tumor to account for tumor motion was not a viable option. In addition to target motion, it is also critical that the radiation oncologist is confident in the extent of target based on radiographic imaging. Advancements in tumor motion quantification, cancer imaging as well as image-guided radiotherapy have enabled the rapid adoption of SBRT that we observe today.
Recent studies on the radiobiologic effect of single fraction high dose radiotherapy have shed light on the underlying mechanism of radiation damage. The results of these biological studies have been intriguing and the goal of this article is to provide the reader with background in classical radiobiology as well as to summarize the recent advancements in understanding the radiobiology of radiosurgery. We also briefly discuss clinical studies that shed light on radiation tolerance of the brain and spinal cord.
Principles of Radiobiology
The goal of radiotherapy is to achieve local control while minimizing normal tissue toxicity. In standard radiotherapy, dose is deposited in both normal tissue and tumor. Hence, it is important to keep the therapeutic ratio in mind. The therapeutic ratio is defined as in equation [1] :
Probability of tumor cure Probability of complications [1] and is depicted in Figure 1 . The goal of every treatment plan is to shift the complications curve to the right while shifting the tumor control curve to the left in order to maximize the separation between the tumor control and complications curve. This is a key concept because all treatment decisions are based on the therapeutic ratio (7) .
When radiation interacts with matter, it causes the ionization of atoms. Ionization of atoms leads to the formation of free radicals that cause DNA damage. What differentiates radiation-induced DNA damage from other type of DNA damage is that in radiation-induced DNA damage, the lesions are clustered in one location thereby making repair difficult. DNA damage can occur either via direct damage or indirect damage. Direct damage occurs when radiation directly ionizes DNA causing single-or double-strand breaks which, if not repaired, can lead to cell death. Indirect DNA damage, which is more common, is mediated by the formation of hydroxyl radicals from water which then interact with DNA to produce DNA strand breaks. Indirect damage is the predominant way in which DNA is damaged as a result of photon or electron irradiation ("sparsely ionizing radiation"). When alpha particles are used as a radiation source ("densely ionizing radiotherapy"), direct DNA damage predominates (8).
DNA damage can be classified as sublethal damage and potentially lethal damage. Under normal conditions sublethal damage is completely repaired within hours, unless repair mechanisms within cells are overwhelmed by the damage. Potentially lethal damage can only be repaired under conditions that are suboptimal for replication and thus are not readily available in vivo. When DNA repair mechanisms fail to repair the DNA damage, chromosomal instability occurs and cells undergo post-mitotic cell death. While tumors mostly Figure 1: Diagram representing the dose relationship between total dose and tumor control as well as total dose and normal tissue complications. The therapeutic window at a particular dose is the separation between the tumor control and normal tissue complication curves. Figure 1A demonstrates a suboptimal therapeutic ratio. Radioprotectors, radiosensitizers and advances in radiation delivery increase the separation between the normal tissue complications and tumor control curves and thereby optimize the therapeutic ratio as represented in Figure 1B . Optimal therapeutic ratio is achieved when the two curves are maximally separated.
undergo post-mitotic cell death after irradiation, normal cells undergo apoptosis after irradiation.
The probability of cell survival after a single dose of radiation is a function of absorbed dose and is represented by cell survival curves as represented in Figure 2 . The shape of the cell survival curve does not differ much between cell lines and has two characteristic regions: low dose shoulder region and the high dose steep region (9). A simple model for cell death assumes that double-stranded DNA breaks are sufficient to cause cell death. Double-stranded breaks can be achieved by a single electron ("single-hit aberrations") or by two separate electrons ("exchange-type aberrations"). Single-hit aberrations are more likely to result from "heavy radiation" such as protons whereas exchange-type aberrations are more likely to occur from "light radiation" such as electrons and photons. Such a model can be represented by the linear-quadratic formula:
S 5 e 2aD2bD 2 where S represents the cell survival fraction, D represents the dose, a is the number of log kills from the linear portion of the cell survival curve (single-hit aberrations) and b is the number of log kills from the quadratic portion of the cell survival curve (exchange-type aberrations). An interpretation of this model is that the shoulder region of the cell survival curve represents sublethal damage and lethality from accumulation of several sublethal lesions. The a/b ratio is a measure of the relative contributions of single-hit and exchange-type aberrations and represents the dose at which these two components are equal (7) . Tumors that are radioresistant to conventional small dose fractionation have a lower a/b whereas more radiosensitive tumors have a higher a/b (10, 11). To understand this, one can think of the b component as the repair capability of the cell. Since exchange-type aberrations require damage from two separate electrons, each DNA strand break has a higher chance of repair because of the availability of the template strand. Since radioresistant tumors have better DNA repair mechanisms, their b component is larger leading to lower a/b ratio. This principle also applies to normal tissues, which have robust repair mechanisms.
Normal tissue can be thought of as "early responding" or "late responding." Early responding tissues (high a/b) are characterized by cells that have a rapid turnover rate such as skin or digestive tract epithelial cells and thus "early effects" of radiation are apparent within days or weeks. Late tissues (low a/b) have a slow turnover rate, such as neurons, and thus "late effects" are apparent only months or years after irradiation.
In addition to the characteristic radiosensitivities of different cell types, the organization of functional units has an important impact on the delivery of radiation. For organs that are arranged in series, elimination of any functional unit leads to malfunction below that level. Hence, large doses to small volumes of organs in series are more detrimental than small doses to large volumes. An example of an organ in series is the spinal cord. Organs that have functional units arranged in parallel continue to function even if part of that organ is destroyed. Examples of organs arranged in parallel include the lung, liver and kidney. Thus in parallel organs, small doses to large volumes are more detrimental than large doses to small volumes (8, 12).
To understand the utility of fractionation in radiation therapy, one needs to first understand the "4R's of Radiobiology". The 4R's are Repair, Reassortment, Repopulation and Reoxygenation. Repair of sublethal damage in normal tissues between fractions leads to fewer radiation toxicities. However, tumor cells can also undergo repair during that time leading to the cultivation of a more radioresistant tumor subpopulation. The cell cycle stage of cells also has an effect on their radiosensitivities (13) . G2 and M phases of the cell cycle are the most radiosensitive and since any given population of cells are unsynchronized in terms of their cell cycle stage, any given dose of radiation will selective kill a certain population of cells leaving a cell cyclesynchronous radioresistant population. If 4-6 hours are allowed to pass between radiation doses, those radioresistant cells will progress to a more radiosensitive cell cycle stage (reassortment) allowing a greater tumor kill efficiency with the next radiation dose. If longer than 4-6 hours are allowed between radiation fractions, these populations of cells will undergo repopulation. Reoxygenation is also an important principle to understand because changes in blood flow (i.e. oxygenation state) can affect the radiosensitivity of cells (14). When DNA is damaged as a Refer to text for a description of the a/b ratio. The "shoulder" region of the cell survival curve denotes the radiation doses that causes sublethal DNA damage. Fractionating radiotherapy in doses within the "shoulder" region will allow normal tissues to repair the DNA damage. Since tumor cells cannot repair DNA damage due to faulty repair mechanisms, tumor cells remain sensitive to the next dose of radiation. result of direct or indirect DNA damage, oxygen forms peroxides with the damaged DNA molecule stabilizing the damage and preventing repair mechanisms from working effectively. Thus oxygen serves as a radiosensitizer. Due to the poor vascular supply of most tumors, tumors with large volumes often have a hypoxic core that is more radioresistant due to lack of oxygen sensitization. When the outer part of the tumor is eliminated due to radiotherapy, the inner part receives a higher blood flow leading to sensitization of the remaining tumor cells and making them more radiosensitive.
Fractionation is widely used in radiotherapy in order to expand the therapeutic window ( Figure 1) . For a given level of normal tissue toxicity, fractionation produces better tumor control than a single large dose of radiation; however, this does not apply to stereotactic radiosurgery because in SRS, target volumes attempt to avoid normal tissue to minimize damage whereas in conventional radiotherapy, target volumes include normal tissue to account for setup inaccuracies. Time between fractions allows normal tissues to repair sublethal damage, but since most tumors have faulty repair mechanisms, they usually cannot repair DNA damage. Time between fractions also allows normal cells to repopulate thus further reducing normal tissue toxicity. Fractionation also leads to increased tumor kill efficiency due to cell cycle reassortment of tumor cells and potential reoxygenation (7, 8) . In sum, fractionation of radiation allows repetition of the shoulder region of the cell survival curve (Figure 3 ). This leads to the separation of the tumor and normal tissue cell survival curves thereby minimizing normal tissue toxicity while maximizing tumor cell kill.
Radiobiology of Radiosurgery
High doses delivered in a single fraction in SRS and SBRT defied conventional radiobiological wisdom and thus arguments were made against its clinical utility. Opponents of SRS and SBRT suggested that single fraction radiotherapy did not utilize the full potential of interfraction reoxygenation and reassortment within tumor cells. Furthermore, they suggested that the highly conformal plans generated for SRS and SBRT treatment would not adequately cover microscopic disease and very high doses (.40 Gy) as predicted by the Linear-Quadratic model would be required to achieve adequate local control of the tumor (15). However, several studies have shown that doses between 15 and 24 Gy provide adequate local control in the treatment of brain metastases (1, 2, 16, 17) as well as benign tumors such as meningiomas which are controlled with a lower dose (18, 19) . For vestibular schwannomas, an even lower dose of 12-13 Gy in a single fraction provides excellent local control rates of over 90% (20, 21) .
Recent clinical data has shown that single-fraction high dose SBRT is very effective at achieving local control regardless of tumor histology. Guckenberger (22). Wulf et al. showed that patients treated with a "high dose" regimen (3 3 12-12.5 Gy) showed better local control than those patients treated with a "low dose" regimen (3 3 10 Gy) (23). Yamada and colleagues (24) examined 93 consecutive patients with 103 spinal metastases and found that while tumor histology was not a statistically significant predictor of local control, higher radiation dose was associated with better local control (p 5 0.03). Dr. Yamada's group (25) extended their study to patients with extracranial metastases and asked the following question: is local control different between patients treated with a low dose (18-20 Gy) single-fraction SBRT vs. high dose (23-24 Gy)? As predicted, they found that they achieved better local control with high dose SBRT than with low dose SBRT (p , 0.0001). Interestingly, they found that in the high dose group (23-24 Gy), tumor histology was not a statistically significant predictor of local control (p 5 0.90). These findings are at odds with classical radiobiology because classical radiobiology would predict tumor histology as a significant predictor of local control. The rationale for using higher doses per fraction in fractionated radiotherapy is to overcome the "shoulder" of the cell survival curve for radioresistant tumors such as renal cell carcinoma, melanoma and sarcoma. Thus, an important question arises: is the biological effect of single-fraction high dose SBRT different from the effect of conventionally fractionated radiotherapy?
As explained above, since tumor cells undergo repair between fractions of radiation, it is the repair capabilities of the tumor that determines its radiosensitivity. Tumors that can repair DNA damage do not undergo post-mitotic cell death and hence are more radioresistant. However, recent data shows that in single-fraction high dose radiotherapy it is not only DNA damage that initiates cell death; it is endothelial cell inflammation (26) and apoptosis via the sphingomyelin pathway (27) causing subsequent microvascular dysfunction that are the triggers for tumor cell death (28). DNA damage continues to be an important insult to the tumor cell and the interaction between microvascular dysfunction and DNA damage eventually leads to tumor death (two-target model) (29).
Upon exposure to high dose radiation, endothelial cells in the tumor vasculature undergo a wave of apoptosis which stops by 15-20 hours post-irradiation, after which these cells are replaced by fibroblasts. Apoptosis in endothelial cells is mediated by the sphingomyelin pathway. Upon exposure to high dose radiation, acid sphingomyelinase (ASMase) is translocated to the plasma membrane of endothelial cells where it plays a role in generating ceramide from sphingomyelin (30). Deng et al. showed that ceramide biogenesis is required for radiation-induced apoptosis (31). Ceramide release leads to the activation of the apoptotic protein BAX (32). BAX is part of the Bcl-2 family of proteins and is an important proapoptotic regulator. Activation of BAX leads to the release of mitochondrial cytochrome c which signifies commitment of the cell to apoptosis via the intrinsic pathway (33). Endothelial apoptosis peaks within 6 hours after radiation and causes microvascular dysfunction and hence acutely disrupts tumor perfusion (34). This model of acute hypoxia and reperfusion injury has been well described in the cardiology literature in the context of ischemic heart disease. It is important to note that the above described molecular responses do not take place until the dose of radiation exceeds the 10 Gy threshold (34). Thus it is not surprising that Lu et al. (35) found that distinct signaling pathways are activated in response to high or low doses of radiation. At doses ,17 Gy, ceramide is generated via the above described ASMase-mediated pathway. However, at doses $17 Gy, ceramide is also produced by ceramide synthase and this pathway is modulated by ataxia telangiectasia-mutated (ATM) kinase. Under normal conditions ATM kinase represses ceramide synthase. Ch'ang et al. showed that in ATM knockout mice, stem cell radiosensitivity increased 3.7 fold without sensitizing the microvascular response (29).
Endothelial cell apoptosis mediated by the sphingomyelin pathway acts synchronously with DNA damage in cancer stem cells to lead to tumor death. Figure 4 details this interaction. With a single high dose of radiation, tumor stem cells undergo DNA damage. Usually this DNA damage is repaired and stem cells are able to survive which leads to local failure. Rotolo et al. showed that inactivation of DNA damage repair pathways signals the generation of ceramide via the ceramide synthase pathway even at low radiation doses. This suggests that unrepaired double stranded DNA breaks can cause the activation of the ceramide synthase pathway leading to apoptosis (36). Interestingly, when ASMase knockout mice are irradiated, the residual DNA damage is much smaller than when wild type ASMase mice are irradiated. This indicates that in the presence of microvascular dysfunction and reperfusion injury, repair mechanisms fail and tumor cells become more radiosensitive. It is intriguing to note that a similar phenotype is observed post-irradiation when acute hypoxia is artificially induced in ASMase knockout mice by clamping the blood supply of the tumor (T. H. Thin et al., unpublished data). These findings indicate that endothelial apoptosis and DNA damage act in concert to produce tumor cell death.
The finding that microvascular dysfunction is important in tumor cell death, paves the path for the development of a new class of radiosensitizing drugs. Recently, Truman and colleagues (37) showed that VEGF prevented radiation-induced ASMase activation in cultured endothelial cells. In the presence of VEGF inhibitors, the ASMase pathway can proceed unhindered and lead to microvascular dysfunction. However, VEGF inhibition must be achieved within 60 minutes before the administration of high dose radiotherapy. Adding further to the evidence that microvascular dysfunction is mechanistically important in tumor cell death in high dose radiotherapy, Lee et al. (38) studied the combined effects of Gamma Knife radiosurgery (GKRS) and thalidomide (an antiangiogenic agent) or temozolomide (a chemotherapeutic agent) in a rat glioma model. They found that the antitumor effect of GKRS 1 thalidomide were greater than that of GKRS 1 temozolomide further adding evidence that antiangiogenesis agents can serve as radiosensitizers.
As mentioned previously, Greco et al. (25) showed that at higher doses (24-25 Gy) local control is independent of tumor histology. However, delivery of such high doses in a single fraction poses significant risk for normal tissue damage and subsequent treatment-related toxicity. It has been shown that ASMase upregulation and the curative single dose of radiotherapy have an inverse relationship. Hence, the use of radiosensitizers acting on the sphingomyelin pathway or on angiogenesis raises the exciting possibility of dose de-escalation while achieving high local control.
A point of contention in the field has been the applicability of the linear-quadratic (LQ) model in predicting tumor control from SRS (39). The LQ model was generated by using Technology in Cancer Research & Treatment, Volume 11, Number 1, February 2012 in vitro data typically at doses/fraction well below those used in radiosurgery (40) . Also the LQ model is based on the primary assumption that DNA damage is the most important factor causing tumor cell kill. As we have demonstrated, at high dose radiotherapy, microvascular damage is more important and is triggered at doses .10 Gy. For instance, in the treatment of arteriovenous malformations, 10% of patients exhibited obliteration with a conventionally fractionated dose of 42 Gy in 12 fractions (biologically equivalent to 15 Gy in one fraction based on the LQ model) (41). However, in single fraction radiosurgery, 15 Gy yielded approximately 50% obliteration (42). It is not surprising that the LQ model underestimated the AVM obliteration efficiency given that the impact of microvascular and stromal damage at high doses is not accounted for in the model. Several groups have developed modified LQ models to fit clinical data (43-47). Wang et al. have developed a modified LQ model called the generalized LQ (gLQ) model specifically for application in radiosurgery to account for the high doses per fraction. They suggest that sublethal DNA damage in high dose radiation is smaller than with conventionally fractionated small dose radiation because sublethal damage is converted to lethal damage due to increased intensity of the radiation. They tested the gLQ model vs. the LQ model in Hela dataset and found that the gLQ model fit the cell kill data appropriately; however, the LQ model overestimated the actual cell kill (47). Park et al. have developed the universal survival curve (USC) which is a hybrid of two classical radiobiological models: the LQ model and the multitarget model. They assumed that the LQ model was more adept at describing the lower dose shoulder region of the cell survival curve and the multitarget model was more adept at describing the higher dose linear portion of the cell survival curve. They tested the validity of their model using the H460 non-small-cell lung cancer cell line (43). However, both these models do not take into account the emerging understanding of molecular and cellular effects of high dose single fraction radiotherapy which will be important in developing models that accurately predict the effect of high dose radiation on normal tissue as well as tumor cells.
Radiosurgery is an intriguing field and our understanding of the molecular response to SRS is rapidly evolving. Research into radiosensitizers has thus far been disappointing with very few, if any, radiosensitizers proven to be clinically useful. However, the development of animal models, development of irradiators that can simulate SBRT in small animals (48) and future in vitro studies will push the boundaries of our current understanding thereby jumpstarting the development of targeted radiosensitizing agents.
Fractionated Stereotactic Radiotherapy
SRS and SBRT offer tremendous radiobiological advantages; however, because of the high doses used in radiosurgery, only small volumes can be treated effectively, i.e. without a prohibitively high dose spill outside the target volume. Figure 5 demonstrates the geometric advantage of a small treatment volume. To treat large volume tumors, it is sometimes necessary to fractionate SBRT to avoid the potential toxicities associated with dose spill outside the target volume, thus expanding the therapeutic window. Furthermore, fractionation confers classical radiobiological advantages: reoxygenation, reassortment and repair. Kim et al. (49) provided evidence of the advantage of fractionated radiosurgery for large tumors. They performed an in vivo study using a rat 9L gliosarcoma model and showed that fractionated radiosurgery provides a radiobiological advantage in preventing toxicity in late-responding tissues such as the optic nerve. However, one of the main disadvantages of fractionation is decreased tumor cell killing efficiency. Qutob et al. (50) performed an in vitro study to evaluate whether the inducible response after fractionated radiotherapy affects tumor cell radiosensitivity. After accounting for DNA damage and cell cycle changes, they showed that cells that received prior fractionated radiation had increased radioresistance in comparison to cells that were radiation-naïve independent of intrinsic radiosensitivity of the cells. These studies show that although fractionated radiotherapy offers some advantages in the treatment of large tumors, single fraction SBRT is likely more effective at achieving superior local control than fractionated SBRT.
Clinical Radiobiology
Clinically, it is most important to understand the tolerance of normal tissue surrounding the tumor so that the treatment plan can be optimized accordingly. Although human studies to determine the tolerance doses of normal structures are not possible, animal studies as well as retrospective clinical studies have shed light on this issue. Recently a supplement issue of the International Journal of Radiation Oncology, Biology and Physics was published that reviewed the current evidence of all normal structures important in clinical radiation oncology (51). Here, we briefly review only the tolerance doses of the brain, brainstem, optic chiasm, and spinal cord as applicable to radiosurgery and refer the interested reader to the supplement for more in-depth reading.
Brain and Brainstem
The principle late effect of radiosurgery in the brain is radiation necrosis ( Figure 6A and 6B ). Radiation necrosis occurs at a median of 1-2 years after treatment, is irreversible and can mimic tumor recurrence, hence complicating its diagnosis (52, 53) . For radiosurgery, it appears that the dose, volume and region irradiated predict the occurrence of radiation necrosis. In patients who have received previous whole brain radiotherapy, Radiation Therapy Oncology Group conducted a dose-escalation study to define the maximal radiosurgery dose for different target sizes. For ,20 mm, the maximal dose was 24 Gy; for 21-30 mm, the dose was 18 Gy; and for 31-40 mm, the dose was 15 Gy (54). Furthermore, the volume of brain receiving $12 Gy and the location (occipital and temporal) have been shown to be correlated with the development of radiation necrosis in the treatment of vascular and non-vascular lesions of the brain (55, 56) .
Toxicity data regarding radiosurgery-induced injury to the brainstem are found in only five studies; however, each study used a wide range of prescription doses and isodose levels (57). The largest study by Foote et al. studied 149 patients and found that the dosimetric factors that are predictive of cranial nerve palsy included Dmax $17.5 Gy, prescribed dose $12.5 Gy, length of irradiated cranial nerve $16 mm and tumor volume $1.7 cc. Based on this data, the authors concluded that doses $15 Gy to the brainstem conferred a significant increase in risk for cranial nerve complications (58). At our institution, we have evaluated the efficacy of Gamma Knife radiosurgery for the treatment of single brainstem metastasis. Forty three patients were treated with a median dose of 15 Gy (range, 9.6-24) , achieving 85% local control at one year; we observed no Grade 3 or 4 toxicities in these patients (16) . At the Cleveland Clinic, we attempt to limit the volume of brainstem receiving 12 Gy or more for Gamma Knife radiosurgery.
Optic Chiasm
Radiation-induced optic neuropathy (RION) is uncommon but severely disabling (59). It is the result of radiation damage to the anterior visual pathway leading to profound visual loss (60). In radiosurgery, the risk of developing RION is estimated to be 0-2% if the optic apparatus is constrained to ,10 Gy (61, 62). However, when the dose to the optic apparatus exceeds 12 Gy, the risk rises rapidly and is 78% with doses $15 Gy (63). At the Cleveland Clinic, we limit the maximum point dose to the optic chiasm to 10 Gy in Gamma Knife radiosurgery.
Spinal Cord
Development of spinal cord myelopathy rarely occurs less than 6 months post-radiotherapy and most cases appear within 3 years after completion of radiation treatment (64). Treatment of primary or metastatic spinal tumors with SBRT has been shown to be safe and has caused the development of myelopathy ( Figure 6C and 6D) only rarely (,1%) (65). Long term follow up data is insufficient to calculate a dosevolume relationship especially because of the short survival of patients with spine metastases (66). Ryu et al. studied 177 Figure 6: T1-weighted (A) and FLAIR (B) MRI demonstrates radiation necrosis in the left hemisphere of the brain in a patient treated for metastatic melanoma. The patient underwent resection prior to receiving Gamma Knife radiosurgery (GKRS) (target volume 5 1.2 cc; 2400 cGy prescribed to the 76% isodose; maximum dose 3160 Gy) and subsequent whole brain radiotherapy (3750 cGy in 15 fractions) four months after GKRS. (C) Pre-SBRT MRI of the spine in a patient with spinal metastasis. (D) 3 months post-SBRT MRI of the same patient shows an enhancing lesion in the spine indicative of myelopathy. The maximum cord dose was 13.6 Gy and 8% of the cord received 10 Gy or more. radiation-naïve patients (230 lesions) with 86 patients surviving greater than 1 year after treatment and demonstrated that the tolerance of the spinal cord is at least 10 Gy to 10% of cord volume (67). Sahgal et al. performed a multi-institutional study of 5 myelopathy cases and compared it to 19 patients with no radiation myelopathy post-SBRT. Out of the 5 patients that developed myelopathy, three patients received a maximum point dose of 10.6 Gy, 13.1 Gy and 14.8 Gy in one fraction to the thecal sac. The other two patients received 25.6 Gy in 2 fractions and 30.9 Gy in 3 fractions to the thecal sac. Their analysis showed that a thecal sac maximum point dose of up to 10 Gy in one fraction is safe (68). It is important to note that Sahgal et al. studied the dose to the entire thecal sac rather than the true spinal cord. Aggregating all the available clinical data on spinal cord myelopathy, Kirkpatrick et al. concluded that 13 Gy in 1 fraction or 20 Gy in 3 fractions confers a risk of myelopathy of less than 1% each (65). At the Cleveland Clinic, we limit the maximum point dose to spinal cord to 14 Gy and the cauda equina to 16 Gy. We also limit the spinal cord such that less than 10% receives 10 Gy or more and less than 10% of the cauda receives 12 Gy or more.
Conclusions
Stereotactic radiosurgery and stereotactic body radiotherapy have revolutionized the delivery of radiation therapy. Numerous clinical studies have shown the efficacy of SRS and SBRT in the treatment of primary and metastatic disease all over the body. Recent radiobiological evidence indicates that the mechanism of radiation damage from SRS and SBRT is different from conventionally fractionated radiation. Table I summarizes the differences between 3D conformal radiotherapy, SRS and SBRT. In this article, we have provided the necessary background in classical radiobiology to understand the rationale behind fractionated radiotherapy and how those principles translate to SRS and SBRT. We have also detailed our current understanding of the molecular response to radiosurgery and how understanding these signaling pathways will lead to the development of radiosensitizing agents and potentially allow dose de-escalation leading to further expansion of the therapeutic window and/or improvement in our ability to control tumors. 1) ASMase-dependent generation of ceramide → activation of pro-apoptotic BAX → endothelial cell apoptosis 2) DNA Damage *For stereotactic brain and spine radiotherapy, SRS can be delivered in 1-5 fractions.
**SBRT usually refers to extracranial and extraspinal stereotactic radiotherapy.
